Bioanalytics - Biomolecular

(T0930-06-31) Non-Tissue Based Screening Methods for Selection of Immunohistochemistry Antibody Candidates

(M0930-06-31) Parallel Accelerator and Molecular Mass Spectrometry for Tracing ¹⁴C-Labeled Metabolites

(W0930-06-31) Simultaneous Quantification of Multiple ADC Component Concentrations and DAR Profiling with One Aliquot of Plasma in NHP Toxicology Study by Hybrid LC-MS

(T0930-06-32) Tumor Chip to Study Dynamics between Immunotherapeutics, Tumor Stroma, and Immune Cells

(W0930-06-33) Receptor Occupancy Assay Development Challenges for Rare Targets of Bispecific Drugs

(T0930-06-33) Troubleshooting the Lack of Neutralizing Antibody Activity during Development of an Enzyme-Based nAb Assay

(T0930-06-34) Assessing Parallelism of IFN-beta and IL-29 in Human K2EDTA Plasma Post Stimulation with LPS and PHA

(M0930-06-34) Development and Qualification of an ECLIA Method for the Detection of Fremanezumab in Human CSF

(W0930-06-34) Validation of an LCMS Hybrid Assay with EVOSEP Cleanup for the Quantitation of Islet Amyloid Polypeptide in Human Plasma

(T0930-06-35) Analysis of Drug-Antibody Ratio (DAR) of ADC (M9346A-SPDB-DM4) in Rabbit Cornea and K₂EDTA Plasma Using SEC-MS

(W0930-06-35) Development of Rabbit Anti-Mertansine (DM1) Monoclonal Antibodies

(M0930-06-36) 1-Tiered Approach for Anti-drug Antibody Testing in Clinical Study

(W1030-06-31) Comparison of the Performance of Luminex-Based and MSD-Based Immunogenicity Assays for Multivalent HPV Vaccines

(M1030-06-31) Utilizing LC-MS to Support of PABAD-Based Detection of Neutralizing Antibodies

(W1030-06-32) An Electrochemiluminescence (ECL)-Based Assay for the Specific Detection of Neutralizing Anti-CAEL-01 Antibodies in Human Serum with a Pre-Treatment Procedure to Eliminate Therapeutic Drug

(T1030-06-33) Development of Novel Cis-Receptor Occupancy Method for Bispecific Antibodies

(W1030-06-33) Development of Sensitive Free and Total Assays for the Quantification of Soluble CD200R1 in Human Plasma Samples to Assess Drug-Target Engagement

(W1030-06-34) Stabilization of a Therapeutic Peptide for a Quantitative ECLIA Assay

(T1030-06-36) Liquid Chromatography – Tandem Mass Spectrometry for Quantification of Zymostenol and Lathosterol in Human Serum with High Specificity and Low Background Noise

(M1130-06-31) Phenyl SPE: A Promising Alternative to More Common Oligonucleotide Extraction

(M1130-06-33) A Derivatization-Free LCMS Assay for 4β-Hydroxycholesterol

(M1130-06-34) Comparison of Platform Sensitivities: Correlation of Endogenous Neurofilament-Light Chain Concentration Determination in Human Serum and K₂EDTA Plasma across Immunoassay Platforms

(M1130-06-35) Maintaining Pristine Structure for High-Purity Isolates: A Combined Method for Nuclei and Mitochondria

(M1130-06-36) A Cell-To-Cell Contact Immune System Mimicking In Vitro Overlay Assay: Evaluating Nanoparticle Vaccine Formulations for Adaptive Immunity Responses

(T1230-06-31) A Technical Evaluation of Targeted Protein Quantification in Formalin Fixed Paraffin Embedded Tumor Sections by Mass Spectrometry Including Antibody Drug Conjugates (ADC)

(T1230-06-32) Plasmon-Waveguide Resonance Spectroscopy to Evaluate Mucin and Phage-like Particle (PLP) Interactions

(T1230-06-34) PEGylated Nanoparticles Conjugated with LHRH Receptor Binding Peptide for Treatment of Lung Cancer

(T1230-06-36) Quantitative Assessment of mRNA Drug Biological Activity by Cell-Based Assays

(T1330-06-31) Method Development and Validation of a Cell-Based Assay for the Detection of Anti-AAV Neutralizing Antibodies in Human Serum

(M1330-06-31) Optimising the Extraction of Oligonucleotides by SPE

(T1330-06-32) Bombesin-Tagged Nanobubbles as Ultrasound Contrast Agents for Prostate Cancer Diagnosis

(M1330-06-33) Plasma and Liver Pharmacolipidodynamics of Gefitinib after Intravenous Administration to Mice Using LC-MS/MS and MS Imaging

(T1330-06-33) Ultra-High Throughput HILIC-Free Analysis of Oligonucleotides Using Acoustic Ejection Mass Spectrometry

(T1330-06-34) LC-MS/MS Method for the Quantitation of Each Monoclonal Antibody (from a 6-Components Antibody Cocktail Drug Product) in Human Serum Matrix

(M1330-06-34) Use of Derivatization for a Sensitive and Selective Liquid Chromatography–Mass Spectrometry Method for Quantification of Acetaldehyde in Plasma

(T1330-06-36) A GxP-Qualified dPCR-Based RCL Assay to Quantify Replication Competent Lentivirus in Bioanalytical Samples

(M1330-06-36) Establishment of an Immunoassay to Quantify Total TL1α Target in Monkey Serum Samples

(M1430-06-31) A Sensitive Bioanalysis Method for Antisense Oligonucleotides using LC-MS/MS

(M1430-06-32) Development of Sensitive Method for Antisense Oligonucleotide Therapeutics Using SIMOA Technology

(T1430-06-32) High Throughput N-glycan Analysis of Heavily Glycosylated Protein Therapeutics to Support Real-Time %sialylation Monitoring for Upstream Bioreactors

(M1430-06-33) The Impact of Unique Stable Label Peptide Internal Standards toward Large Molecule Applications for LC-MS/MS

(T1430-06-35) Comparative Analysis of High-Throughput RNA Extraction Kits in Naïve Non-Human Primate Tissues for Downstream Applications Utilizing Xeno Internal Positive Control (IPC)

(T1430-06-36) Addressing Target Interference During the Development of a Neutralizing Anti-Drug Antibody Assay for the Clinical Support of a Bispecific Therapeutic Antibody